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Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase
inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed
the activity of DTG in HIV-1–infected subjects with genotypic evidence of RAL resistance.
Methods. Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continu-
ing a failing regimen (without RAL) through day 10, after which the background regimen was optimized, when
feasible, for cohort I, and at least 1 fully active drug was mandated for cohort II. The primary efficacy end point
was the proportion of subjects on day 11 in whom the plasma HIV-1 RNA load decreased by ≥0.7 log10 copies/mL
from baseline or was <400 copies/mL.
Results. A rapid antiviral response was observed. More subjects achieved the primary end point in cohort II
(23 of 24 [96%]), compared with cohort I (21 of 27 [78%]) at day 11. At week 24, 41% and 75% of subjects had
an HIV-1 RNA load of <50 copies/mL in cohorts I and II, respectively. Further integrase genotypic evolution was
uncommon. Dolutegravir had a good, similar safety profile with each dosing regimen.
Conclusion. Dolutegravir 50 mg twice daily with an optimized background provided greater and more
durable benefit than the once-daily regimen. These data are the first clinical demonstration of the activity of any
integrase inhibitor in subjects with HIV-1 resistant to RAL.
Keywords. Dolutegravir; DTG; S/GSK1349572; integrase inhibitor; raltegravir resistance.
Integrase inhibitors (INIs) represent a class of drugs
for the treatment of human immunodeficiency virus
(HIV)–infected individuals, blocking HIV genome in-
tegration into the host cell DNA [1]. They have been
shown to be highly effective for the treatment of anti-
retroviral-naive and antiretroviral-experienced sub-
jects, as demonstrated first with raltegravir (RAL) and
more recently with elvitegravir (EVG) [2–6]. However,
these first-generation INIs share common resistance
pathways. In clinical studies of RAL, subjects with
virologic failure and reduced RAL susceptibility typi-
cally harbored virus with 1 of 3 signature mutational
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pathways (ie, N155H, Q148H/K/R, or Y143C/H/R) in the in-
tegrase gene [7]. Continuing RAL treatment in these circum-
stances may lead to the addition of secondary mutations or
pathway evolution; N155H may evolve to Y143 or Q148 path-
ways [4]. In addition, EVG does not appear to have activity
against RAL-resistant isolates, and RAL does not appear to
have activity against EVG-resistant isolates [8–10]. Therefore,
there is a need for an INI with a high barrier to resistance and
activity in subjects with human immunodeficiency virus type
1 (HIV-1) resistant to EVG and RAL.
Dolutegravir (DTG) is a new HIV-1 INI that has demonstrat-
ed good efficacy and safety in treatment-naive, HIV-infected
individuals [11]. In vitro studies demonstrate limited cross-
resistance between DTG and RAL or EVG, with no or minimal
impact on DTG fold-change against Q148 single mutants or
against viruses with Y143 or N155 signature mutations regard-
less of RAL-associated secondary mutations [12, 13]. However,
the DTG fold-change increased for Q148H/K/R as secondary
RAL resistance–associated mutations increased. On the basis of
these in vitro findings, this phase IIb pilot study was conducted
to assess and demonstrate the activity of DTG in HIV-1–infect-
ed individuals with RAL-resistant viral isolates.
METHODS
Study Design
VIKING (ING112961) is a phase IIb, multicenter, open-label,
single-arm, pilot study with 2 sequential cohorts of HIV-1–
infected individuals with current or historic RAL treatment
failure and evidence of RAL resistance at screening. The
50-mg once-daily dose of DTG was initially selected for
evaluation (cohort I); however, the viral load response of some
subjects prompted protocol amendment and subsequent eval-
uation of DTG 50 mg as a twice-daily regimen (cohort II). For
inclusion in cohort I, subjects were screened from August
2009 to October 2009; for inclusion in cohort II, subjects were
screened from June 2010 to October 2010.
The study treatment phases for both cohorts consisted of an
initial 10-day period, when DTG was administered with the
failing background regimen (RAL was discontinued prior to
DTG dosing), followed by a second phase (day 11 onward),
when DTG therapy was maintained but the background
therapy could be optimized according to genotypic and phe-
notypic tests. Subjects remained in the study through at least
24 weeks if they were receiving a clinical benefit from partici-
pating. Subjects were allocated at screening to 1 of 2 groups
on the basis of integrase genotype, as specified in Figure 1,
with capping, as appropriate, to ensure balanced distribution
of subjects between the 2 groups. The 2 groups were not used
for analysis; their purpose was to secure a broad range of DTG
sensitivity in the enrolled population.
Study visits were conducted at screening; on days 1, 6–8, 10,
11, and 21; and at weeks 4, 8, 12, 16, 20, and 24. The study
was conducted in France, Italy, Canada, Spain, and the United
States and was approved by the respective regulatory authori-
ties in each country and by the ethics review committee asso-
ciated with each of the 25 study sites. Written informed
consent was obtained from each individual before screening.
Protocol summaries are posted online (http://www.
clinicaltrials.gov [clinical trials registration NCT00950859]
and http://www.gsk-clinicalstudyregister.com [112961]).
Subjects
Antiretroviral therapy (ART)–experienced, HIV-1–infected
adults (≥18 years of age) with plasma HIV-1 RNA levels of
≥1000 copies/mL, genotypic INI resistance, and documented ge-
notypic and/or phenotypic resistance to ≥1 compound in each
of 2 other approved classes of ART (nucleoside reverse tran-
scriptase inhibitors [NRTIs], nonnucleoside reverse transcriptase
inhibitors [NNRTIs], protease inhibitors [PIs], and fusion/entry
inhibitors) were eligible for enrollment. The availability of ≥1
fully active ART agent for the optimized background regimen
was encouraged for cohort I but mandated for cohort II eligibil-
ity. Exclusion criteria included preexisting mental, physical, or
substance abuse disorders that could interfere with study
conduct; a screening alanine aminotransferase concentration of
≥5 times the upper limit of normal; or a screening lipase con-
centration of ≥3 times the upper limit of normal. Pregnant or
breast-feeding women were excluded. Given available data on
drug-drug interactions, subjects were not enrolled if they were
currently receiving or anticipated requiring efavirenz, nevirapine,
fosamprenavir/ritonavir, or tipranavir/ritonavir. Etravirine
(ETR) was required to be coadministered with lopinavir/ritona-
vir or darunavir/ritonavir (DRV/r) within 15 days of DTG
dosing and/or during the study, to avoid subject exclusion.
Figure 1. Study design. Subjects received dolutegravir (DTG) 50 mg
once daily (cohort I) or DTG 50 mg twice daily (cohort II). In both cohorts,
subjects were allocated to 1 of 2 groups on the basis of integrase geno-
type at screening, to ensure a broad representation of genotypes and a
range of phenotypic susceptibility. Cohort II subjects were required to
have ≥1 fully active antiretroviral therapy in an optimized background
regimen (OBR). Abbreviation: RAL, raltegravir. aQ148H/K/R plus changes
in L74, E138, or G140. bSubjects remained on failing background regimen
from day 1 to day 10.
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Efficacy Assessments
The primary efficacy end point was the proportion of subjects
on day 11 with a plasma HIV-1 RNA load of <400 copies/mL
or of ≥0.7 log10 copies/mL below the baseline value, as quanti-
fied by the Abbott RealTime HIV-1 amplification assay
(Abbott Molecular, Des Plaines, IL). Secondary efficacy end
points included at day 11 and subsequent visits were as
follows: mean change from baseline in plasma HIV-1 RNA
level; proportion of subjects with plasma HIV-1 RNA loads of
<400 and <50 copies/mL, on the basis of the time to loss of
virologic response algorithm; and change from baseline CD4+
T-cell count.
Protocol-defined virologic failure was defined in relation to
baseline plasma HIV-1 RNA levels, as follows: at day 11, a
decrease of <0.7 log10 copies/mL, unless a level of <400 copies/
mL was achieved; at weeks 8 to <16, a decrease of <1.0 log10
copies/mL, unless a level of <400 copies/mL was achieved, or
an increase of ≥1.0 log10 copies/mL from the nadir level; and
at weeks ≥16, a level of ≥400 copies/mL.
Safety Assessments
Safety parameters, including adverse events (AEs), laboratory
parameters, electrocardiogram findings, and vital signs, were
evaluated at scheduled time points and when clinically indi-
cated. The severity of AEs and laboratory abnormalities was
reported and assessed using the grading table of the Division
of Acquired Immunodeficiency Syndrome, National Institute
of Allergy and Infectious Diseases [14]. All available safety
data as of the week 24 data cutoff for each cohort are present-
ed here.
Viral Genotyping and Phenotyping Assessments
Genotypic and phenotypic assays were performed on plasma
samples by Monogram Biosciences (South San Francisco,
CA), using PhenoSense and GenSeq testing methods for
NRTIs, NNRTIs, PIs, and INIs; PhenoSense Entry testing for
enfuvirtide (T-20) susceptibility; and the Trofile assay for mar-
aviroc (MVC) susceptibility. Phenotypic susceptibility was re-
ported as the fold-change relative to that for wild-type virus.
The phenotypic susceptibility score is the total number of
ART drugs in the background regimen to which a subject’s
HIV is fully susceptible on the basis of phenotypic testing.
Baseline integrase genotypic resistance data were used to
produce 6 categories for analysis that were based on mutation-
al pathway: (1) Q148 + 1 (associated mutation at 1 of codons
74, 138, or 140 but not at codons 155 or 143); (2) Q148 + 2
(associated mutations at 2 of codons 74, 138, or 140 but not at
codons 155 or 143); (3) mixture (mutations at codons 148,
155, or 143); (4) N155 (mutations at codon 155 but not at
codons 148 or 143); (5) Y143 (mutations at codon 143 but not
at codons 148 or 155); and (6) other (no mutations at codons
148, 155, or 143). A comparison of on-treatment to day 1
genotypic and phenotypic data was made for all subjects with
data available at day 11 (only samples with a plasma HIV-1
RNA level of ≥150 copies/mL were tested) and for subjects
meeting the criteria for protocol-defined virologic failure.
Statistical Analysis
A single-arm cohort with 30 subjects (cohort I) has ap-
proximately 90% power to distinguish between a failure
rate of 10% and ≥40% at a 2-sided α level of 0.05, while a
single-arm cohort with 20 subjects (cohort II) has approxi-
mately 80% power to detect such a difference. The intent-
to-treat exposed population consisted of subjects who re-
ceived ≥1 dose of DTG and who had ≥1 on-treatment
measure of plasma HIV-1 RNA level. Baseline characteris-
tics and antiviral activity, by cohort, were summarized
using descriptive statistics. The last observation carried
forward and discontinuation equals baseline data set was
used for the primary efficacy analysis, change from baseline
in CD4+ T-cell count, and HIV-1 RNA level at week 24.
The assessment of response at week 24 below a fixed
threshold was calculated according to the US Food and
Drug Administration’s time to loss of virologic response al-
gorithm [15].
The antiviral activity on day 11 between the 2 cohorts was
compared using a linear regression model, with adjustment
for baseline viral load, DTG fold-change relative to wild-type
virus at baseline, phenotypic susceptibility score of the failing
background regimen (days 1–10), and the integrase mutational
pathway at baseline. The population evaluated for safety in-
cluded all subjects who received ≥1 dose of DTG.
RESULTS
Demographic and Baseline Characteristics
Of 53 and 54 subjects screened for cohorts I and II, respective-
ly, 27 and 24 subjects were enrolled to compose the intent-to-
treat exposed populations. Demographic and baseline charac-
teristics generally were similar for the 2 cohorts (Table 1).
Subjects were predominantly white men, with a median age of
48 years. Twenty-six percent and 29% of the subjects in
cohorts I and II, respectively, had advanced HIV disease,
defined on the basis of a CD4+ T-cell count of <50 cells/mm3.
Both cohorts had extensive previous ART treatment, although
more subjects in cohort I had received ETR, DRV/r, and/or
T-20. Because, by design, cohort II subjects should have received
≥1 fully active optimized background regimen component
from day 11, only 1 cohort II subject (4%) had an optimized
background regimen phenotypic susceptibility score of 0, com-
pared with 12 subjects (44%) in cohort I (treatment for this
subject was not a protocol violation because the activity of the
fully active background agent was lost between screening and
baseline). Baseline resistance data indicated the most common
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fully active optimized background regimen components to be
tenofovir (n = 9), ETR (n = 5), DRV/r (n = 4), MVC (n = 2),
and T-20 (n = 2) for cohort I and DRV/r (n = 11), ETR
(n = 9), tenofovir (n = 7), MVC (n = 4), and T-20 (n = 3) for
cohort II.
The median baseline RAL fold-change was greater than the
maximum concentration tested for viruses isolated from both
cohorts I and II (Table 1). In contrast, the median fold-change
for DTG was low (cohort I, 1.46; cohort II, 2.72), with low-
to-moderate values for Y143 and N155H pathway viruses
(Figure 2) but higher values for viruses with mutations at
Q148.
Efficacy
Ninety-six percent of subjects (23 of 24) in cohort II and 78%
of subjects (21 of 27) in cohort I achieved the primary end
point (ie, a reduction in plasma HIV-1 RNA level of ≥0.7
log10 copies/mL below the baseline value or a level of <400
copies/mL at day 11; Table 2). Thirteen subjects (54%) in
cohort II and 11 subjects (41%) in cohort I achieved an HIV-1
Table 1. Demographic and Baseline Characteristics for the Intent-to-Treat Exposed Population
Parameter Cohort I, DTG 50 mg Once Daily (n = 27) Cohort II, DTG 50 mg Twice Daily (n = 24)
Age, y 48 (19–61) 47 (33–68)
Male sex 25 (93) 18 (75)
Race
White, Caucasian/European heritage 23 (85) 18 (75)
White, Arabic/North African heritage 1 (4) 1 (4)
African American/African heritage 3 (11) 5 (21)
CD4+ T-cell count, cells/mm3 114 (19–729) 202 (19–528)
Plasma HIV-1 RNA level, log10 copies/mL 4.5 (2.6–6.1) 4.3 (3.3–5.8)
CDC class C disease 16 (59) 8 (33)
Hepatitis virus coinfection
HBsAg positive 0 2 (9)
HCV antibody positive 2 (7) 6 (26)
HBV or HCV status missing 4 (15) 2 (9)
HBsAg and HCV antibody positive 0 0
Duration of prior ART, y 14 (4–21) 15 (3–22)
No. of prior ART drugs 17 (6–24) 15 (6–19)
Prior ART treatment
Etravirine 19 (70) 11 (46)
Enfuvirtide 22 (81) 13 (54)
Darunavir/ritonavir 23 (85) 14 (58)
Maraviroc 10 (37) 9 (38)
Current RAL failure 21 (78) 20 (83)
Baseline INI resistance/integrase mutational pathway
Q148H/K/R + 2 mutationsa 3 (11) 2 (8)
Q148H/K/R + 1 mutationsa 4 (15) 8 (33)
Mixed Q148H/K/R with Y143C/H/R or N155H 2 (7) 1 (4)
N155H 4 (15) 6 (25)
Y143C/H/R 12 (44) 6 (25)
Otherb 2 (7) 1 (4)
Baseline DTG FC 1.46 (0.55–35) 2.72 (0.87–9.48)
Baseline RAL FC >161 (0.6–166) >128 (0.8–183)
PSS of failing regimen= 0c 18 (67) 15 (63)
PSS of OBR= 0 (on day 11) 12 (44) 1 (4)
Data are no. (%) of subjects or median (range).
Abbreviations: ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; DTG, dolutegravir; FC, fold change in 50% inhibitory concentration;
HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; INI, integrase inhibitor; OBR, optimized background regimen; PSS,
phenotypic susceptibility score; RAL, raltegravir.
a Mutations at L74, E138, or G140.
b Subjects with no Q148, Y143, or N155 mutations at day 1.
c PSS on fully active agents.
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RNA level of <400 copies/mL on day 11. The respective
numbers for subjects with HIV-1 RNA levels of <50 copies/
mL were 4 (17%) and 3 (11%). In a multivariate analysis that
controlled for baseline factors, cohort II had a significantly
larger reduction in HIV-1 RNA level from baseline on day 11,
compared with cohort I (mean adjusted treatment difference,
−0.32 log10 copies/mL; −1.76 vs −1.45 log10 copies/mL;
P = .017).
At week 24, the response rate was greater in cohort II: 18
subjects (75%) had a plasma HIV-1 RNA level of <50 copies/
mL, in contrast to 11 subjects (41%) in cohort I (Table 2). The
response rates increased in both cohorts as the number of
fully active agents in the optimized background regimen in-
creased. The CD4+ T-cell count increased from baseline in
both cohorts through week 24 (median increase, 54 and 60
cells/mm3 for cohorts I and II, respectively).
New HIV-associated conditions were reported for 4 subjects
in cohort I and 1 subject in cohort II through week 24. These
conditions included oropharyngeal candidiasis, herpes simplex
virus infection, immunoblastic lymphoma, and a brain mass
in cohort I and oropharyngeal candidiasis in cohort II.
Safety
The safety profile of DTG was similar in both cohorts.
Adverse events (grade ≥2) were reported by 13 subjects (48%)
and 16 subjects (67%) in cohorts I and II, respectively
(Table 3), but no obvious trend in increased reporting of any
individual parameter was observed in cohort II. Serious AEs
were reported in 4 and 3 subjects in cohorts I and II, respec-
tively; none of these were considered related to DTG treat-
ment, and no specific serious AE was reported by >1 subject.
Two deaths were reported in cohort I: 1 subject with an im-
munoblastic lymphoma/bone marrow aplasia died during a
second course of chemotherapy, and 1 subject died, after study
withdrawal, with an undiagnosed brain mass. There were no
other study discontinuations due to AEs in cohort I. In cohort
II, there were no deaths or discontinuations due to AEs.




Daily (n = 27)
Cohort II, DTG
50 mg Twice
Daily (n = 24)
Efficacy at day 11
Primary end point, no. (%) 21 (78) 23 (96)
Plasma HIV-1 RNA level, log10 copies/mL
Baseline, mean (SD) 4.40 (0.79) 4.38 (0.74)
Day 11, mean (SD) 2.94 (1.01) 2.62 (0.78)
Change from baseline,
mean (SD)
−1.45 (0.77) −1.76 (0.54)
Model-adjusted change,
mean (SD)




−0.32 (−0.57 to −0.06)b
Efficacy at week 24
HIV-1 RNA load, copies/mL, no. (%)c
<50 11 (41) 18 (75)
<400 14 (52) 20 (83)
<50, by baseline PSS to OBR at day 11
PSS= 0 1/12 (8) 1/1 (100)
PSS = 1 4/7 (57) 6/9 (67)
PSS ≥ 2 6/8 (75) 11/14 (79)
HIV-1 RNA load <50 copies/mL, no. (%)c
Responder 11 (41) 18 (75)





11 (41) 4 (16)
Rebound 2 (7) 1 (4)
Discontinued study drug
or added new ART
before achieving
confirmed suppression
3 (11) 1 (4)
AE/death 2 (7)d 0
Nonpermitted change
in ART
1 (4) 1 (4)




−1.3 (1.29) −2.3 (1.05)
Change in CD4+ T-cell
from baseline, cells/
mm3, median (IQR)e
54.0 (0–118.0) 60.0 (0–145.5)
Abbreviations: AE, adverse event; ART, antiretroviral therapy; CI, confidence
interval; DTG, dolutegravir; IQR, interquartile range; LOCFDB, last observation
carried forward and discontinuation equals baseline; OBR, optimized
background regimen; PSS, phenotypic susceptibility score; TLOVR, time to loss
of virologic response.
a Cohort II vs cohort I.
b P = .017.
c Based on TLOVR algorithm.
d One subject with brain mass subsequently died. One subject with febrile
bone marrow aplasia died on the last date of DTG administration.
e Analysis based on LOCFDB data set at week 24 visit.
Figure 2. Dolutegravir (DTG) fold-change (FC) in 50% inhibitory con-
centration at baseline, by integrase (IN) mutational pathway at baseline.
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The proportion of grade 3 treatment-emergent laboratory
abnormalities was similar between cohorts (cohort I, 22%;
cohort II, 21%), and only 1 subject in cohort II experienced a
grade 4 laboratory abnormality (neutropenia). Of the grade 3
abnormalities, elevated total and low-density lipoprotein
cholesterol, lipase, and bilirubin levels and decreased phos-
phorus level were each reported for 2 subjects in both
cohorts combined. In both cohorts, modest mean increases
in creatinine concentration were noted; increases were
evident by days 6–8 (mean increase, 0.084–0.105 mg/dL),
reached a plateau at week 4 (mean increase, approximately
0.14 mg/dL for both cohorts), and remained stable to week
24. No subject had a grade 3 or 4 increase in creatinine
values, and renal toxicity did not result in withdrawal of any
subjects.
Virologic Resistance
To assess the evolution of integrase resistance in the context of
DTG coadministered with failing background therapy, 18 of
27 subjects in cohort I and 15 of 24 subjects in cohort II had a
sufficient plasma HIV-1 RNA level (≥150 copies/mL) on day
11 for assessment. Viruses from only 2 of 18 subjects in
cohort I and 3 of 15 subjects in cohort II demonstrated emer-
gence of additional integrase resistance mutations, a reduction
in DTG susceptibility, or both on day 11 (Table 4). Four of
these 5 subjects harbored virus with Q148H plus ≥1 addition-
al RAL resistance–associated mutation at day 1. Of these 4
subjects, 3 had an increase in DTG fold-change for the day 11
virus, while no phenotypic result was obtained for virus from
the fourth subject. The fifth subject (S1) harbored a virus
from the Y143R pathway at day 1 and, despite detection of an
E138E/K mixture at day 11, DTG fold-change remained un-
changed from baseline. All 3 subjects in cohort II had a phe-
notypic susceptibility score for their failing regimen of 0, and
the 2 subjects in cohort I each had a phenotypic susceptibility
score of 1. Both subjects in cohort I and 1 subject in cohort II
were able to reach a plasma HIV-1 RNA level of <400 copies/mL
after day 11.
Protocol-defined virologic failure was observed through
week 24 in 12 subjects (44%) and 5 subjects (21%) in cohorts
I and II, respectively. Ten of the 12 cohort I subjects had an
optimized background regimen phenotypic susceptibility score
of 0, in contrast to none of the 5 cohort II subjects. Treat-
ment-emergent INI genotypic resistance was observed in virus
isolated at protocol-defined virologic failure for 4 of the 12
cohort I subjects and 3 of the 5 cohort II subjects, accompa-
nied by an increase in DTG fold-change (Table 5). At virolog-
ic failure, all 7 subjects harbored ≥4 RAL resistance–
associated mutations, and 5 of the 7 subjects (2 in cohort I; 3
in cohort II) had virus with Q148 +≥1 RAL resistance–associ-
ated mutation at screening or baseline. Virus from 4 of the 7
subjects had emergent N155H detected at virologic failure;
however, the impact of this acquisition on the absolute DTG
fold-change at protocol-defined virologic failure was depen-
dent on the starting pathway virus.
DISCUSSION
VIKING is the first study to explore DTG treatment of HIV-
1–infected subjects who had experienced virologic failure
during receipt of a RAL-containing regimen and had genotyp-
ic evidence of RAL resistance. Despite the presence of HIV-1
with a very high level of resistance to RAL, a rapid antiviral
response was observed in both cohorts, with a better response
rate for the primary end point at day 11 in cohort II (96%)
than in cohort I (78%). In a linear regression model account-
ing for differences in baseline factors and phenotypic suscepti-
bility score of the continued failing regimen, the reduction in
plasma HIV-1 RNA level at day 11 was shown to be signifi-
cantly greater (P = .017) in cohort II than in cohort I. The
twice-daily 50-mg dose of DTG was assessed in cohort II
because clinical pharmacology data with DTG 100 mg once
daily had indicated a solubility limit to DTG and because
pharmacokinetic/pharmacodynamic modeling had predicted
better long-term antiviral effects with DTG 50 mg twice daily
against RAL-resistant viruses with greater fold-change in sus-
ceptibility to DTG [16]. The results presented here support
these assumptions.
This study included highly treatment-experienced popu-
lations with HIV-1 resistant to most approved ART drugs
and to RAL, and although the baseline viral isolates gener-
ally had relatively low fold-change in DTG susceptibility,
the range of susceptibility to DTG allowed an appropriate
test of this new INI. The baseline phenotypic susceptibility
to DTG was narrower in cohort II, with no viruses
showing a fold-change of ≥10 in susceptibility to DTG
when compared with cohort I. Given the relatively small
sample size and the fact that 23 of 24 subjects in cohort II
responded to DTG, a phenotypic cutoff for DTG activity
could not be established.
Table 3. Summary of Grade ≥2 Adverse Events
Grade ≥2 AE
Cohort I, DTG 50 mg
Once Daily (n = 27)
Cohort II, DTG 50 mg
Twice Daily (n = 24)
Any 13 (48) 16 (67)
Diarrhea 1 (4) 2 (8)
Insomnia 3 (11) 0
Bronchitis 1 (4) 2 (8)
Cough 1 (4) 2 (8)
Data are no. (%) of subjects and are limited to grade ≥2 AEs occurring in ≥2
subjects in cohort I or cohort II.
Abbreviations: AE, adverse event; DTG, dolutegravir.
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At week 24, more subjects in cohort II than cohort I
achieved plasma HIV-1 RNA levels of <50 and <400 copies/
mL, consistent with the predicted better drug exposure and a
more active optimized background regimen as mandated by
the protocol. Considering only those subjects with an opti-
mized background regimen phenotypic susceptibility score of
1, the proportion of subjects achieving <50 copies/mL at week
24 was higher in cohort II, compared with cohort I (67% vs
57%). In both cohorts, subjects experienced an immunological
response, with a median increase in CD4+ T-cell count of 54–
60 cells/mm3 by week 24.
DTG generally was well tolerated when administered at
either 50 mg once daily or 50 mg twice daily, consistent with
safety data from other treatment studies [11], and did not
show a clinically significant difference in the safety profile
between the 2 dosages, although the sample size was small.
Reporting rates for laboratory abnormalities were low and
comparable across both cohorts. The modest, early, nonpro-
gressive effect on creatinine level is consistent with inhibition
of a renal transporter, organic cation transporter 2, as dis-
cussed in prior reports on DTG [11].
Resistance emergence during the initial 10-day phase was
limited, with new INI resistance mutations detected in day
11 samples from 2 of 18 cohort I subjects and 3 of 15 cohort
II subjects. Treatment-emergent genotypic resistance was ob-
served in virus at protocol-defined virologic failure at or after
Table 5. Treatment-Emergent Integrase Inhibitor (INI) Resistance Mutations at the Time of Protocol-Defined Virologic Failure (PDVF)
Subject
Integrase
Mutational Group VF Visit PSS
RAL Resistance–Associated Mutationsa DTG FC
Day 1 Time of PDVF Day 1 Time of PDVF
Cohort I
S2 Mixture Day 11 1 G140S, Y143H, Q148H L74I/M, E138E/A, G140S, Q148H 6.49 38
S6 Other Week 8 0 Noneb L74L/M/I, T97A, G140S, Q148H 0.87 68
S7 Y143 Week 24 0 L74M, T97A, E138A, Y143R L74M, T97A, E138A, Y143R, N155H 0.77 6.58
S8 Y143 Week 24 0 L74M, T97A, Y143R L74M, T97A, Y143R, N155H 0.91 8.44
Cohort II
S4 Q148 + 1 Week 16 2 G140S, Q148H T97T/A, E138E/K, G140S, Q148H, N155H 6.23 93
S5 Q148 + 2 Week 8 1 E138A, G140S, Q148H E92E/Q, T97T/A, G140S, Q148H 6.04 42.32
S9 Q148 + 1 Week 8 4 G140S, Q148H E138E/K, G140S, Q148H, N155H 4.11 63
Abbreviations: DTG, dolutegravir; FC, fold-change in 50% inhibitory concentration; PSS, phenotypic susceptibility score; RAL, raltegravir; VF, virologic failure.
a Differences in integrase genotype between day 1 and time to PDVF are bold.
b Subject harbored virus with G140G/S and Q148Q/H at screening.












RAL Resistance–Associated Mutationsb DTG FC
Day 1 Day 11 Day 1 Day 11
Cohort I















S4 Q148 + 1 −1.57 0 G140S, Q148H G140S, Q148H,
N155N/H
6.23 NR
S5 Q148 + 2 −0.9 0 E138A, G140S, Q148H T97T/A, E138T/A,
G140S, Q148H
6.04 21
Abbreviations: FC, fold-change in 50% inhibitory concentration; NR, no results; PSS, phenotypic susceptibility score; RAL, raltegravir.
a In subjects with paired day 1 and day 11 integrase genotype and phenotype.
b Differences in integrase genotype between day 1 and day 11 are bold.
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day 11 from 4 of 12 cohort I subjects and from 3 of 5 cohort
II subjects. All of these subjects harbored 2 or 3 INI resis-
tance mutations at screening or baseline. Across both
cohorts, virus with Q148H + G140S plus additional RAL re-
sistance mutations was more likely to have a greater DTG
fold-change and lower response to DTG treatment. These
results are consistent with the earlier in vitro findings that
mutations at position Q148 with additional INI resistance
mutations can reduce DTG susceptibility [17]. For 2 subjects
in cohort I (both with the Y143 mutation) and 2 subjects in
cohort II (both with Q148 + 1 mutations), the addition of the
N155H mutation to the resistance profile was observed, and,
in each case, 3–4 RAL resistance mutations were present with
N155H. Therefore, a substantial number of well-characterized
INI resistance mutations appear to be required to confer re-
duced susceptibility to DTG in virus from patients previously
treated with RAL with well-documented virologic failure. In
this study, at all positions in the integrase gene that were
evaluated, no DTG-specific resistance mutations have been
identified thus far. Clonal analysis and site-directed mutant
phenotypic analysis of observed mutations are ongoing to
better define the role of these mutations on DTG phenotypic
susceptibility and will be the subject of future analyses. A
clonal analysis of the 4 samples in which the N155H mutation
emerged at the time of virological failure showed that the
emergent N155H mutation and the integrase resistance muta-
tion detected at day 1 were on the same genome [18, 19]. This
result provides further support for the conclusion that high-
level DTG resistance requires multiple RAL resistance muta-
tions. The possibility that the N155H mutation was present as
a low-level minority variant at baseline, which has been ob-
served in other studies of virological failure of first-generation
INI [20], cannot be excluded.
The sequential cohort design, with some differences in
baseline characteristics between cohorts and the mandate of
cohort II subjects to receive ≥1 fully active drug in the opti-
mized background regimen for eligibility, may limit the in-
terpretation of comparisons at week 24. However, the
aggregate clinical and resistance data support the choice of
50 mg twice daily as the appropriate DTG dose to be further
evaluated in patients with INI-resistant virus.
In conclusion, during a period of functional monotherapy in
subjects with limited treatment options and RAL-resistant
HIV-1, DTG 50 mg twice daily provided substantial antiretrovi-
ral activity that was sustained through 24 weeks after optimiza-
tion, when possible, of background therapy. As with other
antiretroviral drugs, durability of response is more likely when
there is support from background drug activity. Integrase resis-
tance emergence during therapy occurred in <15% of all sub-
jects, and the mutations that emerged were previously described
RAL-associated mutations. As yet there is no in vivo evidence
of emergence of novel mutations that result in a substantial
decrease in DTG susceptibility. Because of the improved effica-
cy, good tolerability, and similar safety noted for DTG 50 mg
twice daily, compared with DTG 50 mg once daily, the 50 mg
twice-daily dosage is being evaluated in a larger, ongoing phase
III study (VIKING-3) in a heavily treated HIV-1 infected popu-
lation harboring RAL- or EVG-resistant virus.
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